In this study, we provided evidence that EdgeSeq PIP is a robust assay with a high degree of concordance with multiple platforms, including RNA-seq, tumor/immune cell fraction estimation by H & E staining, PD-L1 scoring and CD8+ T cell abundance estimation by IHC. This evidence concerns the gene CD8A and neoplasm.